Compare THFF & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THFF | OMER |
|---|---|---|
| Founded | 1984 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 940.1M | 844.6M |
| IPO Year | 1995 | 2008 |
| Metric | THFF | OMER |
|---|---|---|
| Price | $79.41 | $19.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $62.00 | $32.50 |
| AVG Volume (30 Days) | 77.8K | ★ 2.4M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | 67.00 | ★ 98.15 |
| EPS | ★ 3.58 | 0.77 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $17.88 | N/A |
| Revenue Next Year | $4.03 | $233.22 |
| P/E Ratio | ★ $22.24 | $25.09 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $51.21 | $3.94 |
| 52 Week High | $84.17 | $19.58 |
| Indicator | THFF | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 86.30 |
| Support Level | $79.72 | $9.12 |
| Resistance Level | $84.00 | N/A |
| Average True Range (ATR) | 1.68 | 0.84 |
| MACD | -0.47 | 0.41 |
| Stochastic Oscillator | 37.70 | 96.99 |
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities. Company's loan portfolio was diversified in Commercial, Residential and consumer domains.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.